

ASX Company Announcement

20 December 2006

HARRINGTON GROUP SEEKS PATENT ENFORCEMENT AGAINST SEVEN MAJOR GLOBAL ILLICIT DRUG MANUFACTURERS

Following advice to the market yesterday of initiation of a patent infringement case against US based Avitar, Harrington Group Limited ("Harrington" or "the Company") wishes to advise that since its acquisition of Sun Biomedical Laboratories Inc, management, along with its legal advisors, has been reviewing and investigating global competitor drug testing products and their respective claims.

The Company advises that it has identified seven major US and European manufacturers that in the opinion of the Company are infringing one or more key patents which combine to provide the unique attributes and competitive differentiation of the Company's premier oral-fluids drug screening device OraLine IV.

The Company advises that on advice it will be taking all such actions as may be necessary to ensure that proprietary technology is protected and/or the company is appropriately recompensed wherein the company may choose to license the use certain intellectual property under appropriate commercial terms.

For further information or inquiry please contact:
Brian Andrews – Managing Director
Tel: +613-8610-6370